Valuation: NEOVACS

Market Cap 4.09K 4.67K 3.77K 3.49K 6.61K 446K 6.73K 45.24K 17.61K 219K 17.53K 17.14K 759K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -229K -185K -171K -325K -21.95M -331K -2.22M -865K -10.78M -862K -843K -37.31M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2020-09-30
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 2003-05-27
Director/Board Member - 2020-04-30
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-1.00% - - 231K
-0.24%+4.98%+2.69%+9.14% 49.74B
-0.36%+1.33%+417.51%+619.10% 40.49B
-2.29%+5.93%+25.27%+59.26% 34.35B
-2.13%+5.47%+25.45%-6.01% 34.75B
-0.79%+2.02%+3.83%+36.42% 26.98B
+3.82%+3.92% - - 16.58B
-2.62%+0.45%+66.82%+125.87% 15.6B
-2.17%+6.52%+102.15%+102.15% 14.27B
-2.70%-2.19%+11.25%+18.19% 13.76B
Average -1.05%+3.99%+81.87%+120.52% 27.39B
Weighted average by Cap. -1.00%+4.37%+93.71%+139.18%

Financials

2023 2024
Net sales 533K 609K 492K 455K 863K 58.24M 879K 5.9M 2.3M 28.6M 2.29M 2.24M 99.02M 434K 495K 400K 370K 702K 47.38M 715K 4.8M 1.87M 23.27M 1.86M 1.82M 80.55M
Net income -8.74M -9.98M -8.07M -7.45M -14.14M -955M -14.4M -96.74M -37.65M -469M -37.49M -36.66M -1.62B -32.91M -37.58M -30.38M -28.06M -53.24M -3.59B -54.21M -364M -142M -1.76B -141M -138M -6.11B
Net Debt -237K -270K -218K -202K -383K -25.82M -390K -2.62M -1.02M -12.68M -1.01M -992K -43.9M -205K -234K -189K -175K -332K -22.39M -338K -2.27M -883K -11M -879K -860K -38.07M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
-